OBJECTIVE: To test the hypothesis that a melanocortin agonist can reverse obesity and insulin resistance in mice overexpressing the agouti protein. EXPERIMENTAL MODEL: Mice overexpressing the agouti protein either by transgene introduction (b b-actin promotor) or by mutation (A y ). DESIGN: NDPMSH was tested for pharmacokinetic suitability. NDPMSH at various doses was administered subcutaneously twice a day for 2 ± 3 weeks. MEASUREMENTS: Fur pigmentation, various fatness parameters (core temperature, fat pad weight and body weight), blood glucose and hormones, fatty acid synthase measurement. RESULTS: NDPMSH caused fur pigmentation and core temperature changes, but failed to affect any metabolic parameters in agouti-dependent manner. CONCLUSION: NDPMSH, as a representation melanocortin agonist, does not compete with agouti in reversing agoutidependent metabolic effects. This suggests that 1) agouti works via a receptor other than a melanocortin receptor to mediate its metabolic effects, 2) agouti-dependent metabolic effects are mediated through melanocortin receptors but not via antagonism of these receptors, or 3) NDPMSH is pharmacodynamically an inappropriate molecule for these types of studies.
Introduction
Dominant mutations at the agouti locus results in mice with yellow coat color that become obese and hyperinsulinaemic. 1, 2 The murine agouti gene encodes for a 131 amino acid secreted protein, normally expressed in the skin during hair growth to regulate pigmentation. 3 Abnormal expression of the agouti protein causes the obese and diabetics, as well as the yellow coat phenotypes, as these are reproduced when the murine agouti cDNA is placed under the transcriptional control of an ubiquitous promoter in transgenic mice. 4, 5 The murine agouti protein normally functions in a paracrine manner to regulate coat colour through competitive antagonism of alpha-melanocyte stimulating hormone (aMSH) binding to the aMSH receptor (melanocortin receptor 1 or MC1R). Agouti protein antagonism prevents the increase in intracellular cAMP produced upon ligand binding. 6, 7 This increase in cAMP leads to the switching of the molecular pathway of pigment production from phaeomelanin to eumelanin. It is possible that the obeseadiabetic phenotype induced by agouti overexpression may occur via altered signalling of other melanocortin receptor (MCR) family members, as they are expressed in energy relevant tissues such as adipose, muscle and brain. 8, 10 Recently, we have shown that agouti antagonizes the MC4R and MC3R receptors with K i 's closer than originally described. 11 In order to test the hypothesis that agouti antagonism of MCRs leads to these phenotypes we introduced norleucine, 4 D-phenylalanine 7 aMSH (NDPMSH), a potent ligand and agonist of all the MCRs, 11, 12 into transgenic mice ubiquitously overexpressing the wild type agouti protein. We report here that while the NDPMSH showed good systemic effects on coat coloration and core temperature regulation, it failed to have any effect on insulin, glucose levels and weight. This suggests that agouti may have effects on a different receptor type than MCRs, or it may mediate its effects on MCRs other than through ligand antagonism.
Methods and materials

Materials
NDPMSH was purchased from Bachem (Philadelphia, PA). Na 125 I was purchased from Amersham (Arlington Heights, IL). Enzymobeads were purchased from BioRad (Hercules, CA).
Cold iodination of NDPMSH
Custom iodinated 10 mg of NDPMSH (Peninsula Labs, Belmont, CA), yielded 8 mg of iodinated peptide. To dissolve the peptide 1 ml of 1 mM HCl was added directly to the vial. All of the material was puri®ed by HPLC (four separate runs). Brie¯y, 0.25 ml of the iodinated peptide solution was loaded onto a Waters Sep-Pak C18 cartridge that had been equilibrated in 50 mM ammonium acetate, pH 5.8 plus 15% acetonitrile. The material was eluted using a peristaltic pump with a 40 ml gradient up to 40% acetonitrile. The mono-and di-iodinated forms of the peptide were collected separately, and vacuum evaporated to dryness. The monofractions from the four runs were redissolved in 1 mM HCl and combined, as were the difractions. Overall yield was 0.8 mg of each of the two iodinated forms, with purity at b 98% as assessed by HPLC. Peak identity was con®rmed by HPLCamass spectrometry (not shown).
Hot iodination of NDPMSH
NDPMSH was radiolabeled using Enzymobeads technology. Brie¯y, the following was placed in a microcentrifuge tube: 50 ml buffer (0.2 M sodium phosphate, pH 7.3), 10 ml 0.6 mM NDPMSH (6 nmol), 50 ml Enzymobeads and 20 ml Na 125 I (2 mCi; 1.2 nmol). The reaction was started by the addition of 25 ml 1% b-d-glucose, and allowed to proceed for 30 min at room temperature. The reaction was stopped by removal of the beads by centrifugation, followed by the addition of 2 ml of 60 mM N-acetyl-tyrosine to the supernatant. Puri®cation was by HPLC as described in the preceding paragraph. The results of ®ve consecutive runs were combined to yield a total of 1.8 mCi of 125 I-NDPMSH. Prior to being concentrated to dryness by vacuum evaporation, nonradioactive I-NDPMSH was added to reduce the speci®c activity to 25 mCiammol.
Animals
C57Bla6J-A y and C57Bla6J mice were purchased from Charles River Laboratories Inc., Raleigh, NC. Transgenic mice ubiquitously overexpressing agouti were generated as previously described. 4 Mice were maintained on a powdered high-fat diet (mouse diet 5015, PMI Feeds, St Louis, MO). At 12 weeks of age, male transgenic mice and littermate controls were treated with NDPMSH or saline (control). Prior to treatment, all mice were anesthetized under iso¯uor-ane and hair was plucked from a 1 cm 2 area on the ventral surface, in order to observe any subsequent effects of NDPMSH administration on pigmentation of newly grown hairs at a site distant from the hormone administration site.
NDPMSH (1, 5 or 10 mgakg body weight) was dissolved in saline and administered subcutaneously on the dorsal surface, between the scapulae. Saline administration served as a control. NDPMSH or saline was administered twice daily for 14 d or 21 d.
The animals were maintained on a 12 h lightadark cycle (light from 07.00±19.00 h). Injections were performed at approximately 18.00 h, and all core temperature measurements were performed prior to injection.
Physiological measurements
Core temperature was measured using a thermocouple (Columbus Instruments, Columbus, OH). Probe insertion was performed on day 0, day 7 and day 14 at a constant distance (1.8 cm) into the rectum. After stabilization (10 s), the temperature was recorded every 5 s for 30 s. All temperature measurements were made between 09.00±10.30 h.
On day 14, animals were anesthetized with iso¯uor-ane following an overnight fast, and blood obtained via cardiac puncture. Fat pads (epididymal, perirenal, retroperitoneal, inguinal and subscapular) were dissected, immediately weighed, frozen in liquid nitrogen and stored at 780 C for subsequent measure-ments of fatty acid synthase activity, as described below.
Blood glucose was measured using a blood glucose monitoring system (Accu-check, Milpitas, CA). Plasma insulin and leptin levels were measured via radioimmunoassay using commercial kits (Linco, St Louis, MO). Fatty acid synthase activity was measured in the subcutaneous and visceral fat depots by a spectrophotometric method 13 as previously described.
14 Protein was determined using a modi®ed Lowry method. 15 All data are presented as mean AE s.e.m. for four groups of mice: Control mice on saline, control mice on NDPMSH, transgenic mice on saline and transgenic mice on NDPMSH. Data were analyzed via two-way analysis of variance or, in the case where only two groups were being compared to characterize transgenic vs control, by Student's t-test.
Pharmacokinetics of 125 I-NDPMSH in mice
Male mice of C57B16 strain with body weight in range 25±30 g were supplied by Charles River Laboratories. Mice were divided into two groups of 28 each. The ®rst group received an intravenous bolus dose of 125 I-NDPMSH via a tail vein. The second group received a subcutaneous dose of 125 I-NDPMSH. The dose was 0.08 mgakg (50 nmolakg, 1000 mCiakg) in all studies. Food and water were provided through the entire experiment. Two mice were randomly assigned to each time point except the last time point consisting of four mice. At each time point, except at 72 h, mice (n 2) were killed to only collect blood samples. Blood, urine and feces were collected from the 72 h time point group (n 4). The were centrifuged to separate the plasma. The plasma samples were stored in a freezer at 775 C. Red blood cells were discarded. Predose, 0±24, 24±48, 48±72 h urine and fecal samples were collected from the 72 h time point group (n 4) and stored in a freezer at 775 C. Samples were extracted with acetonitrile and were analyzed as essentially described for the puri®-cation of the NDPMSH iodinated forms.
Results
Rationale for using NDPMSH
While previous experiments have been performed using the natural ligands, aMSH and des-acetyl MSH, 16, 17 it is also clear that these ligands have extremely short half-lives in serum and are labile to a number of proteases. 18 To overcome these issues, we used a stable, potent analog, NDPMSH. 12 To determine the various pharmacokinetic parameters of this compound, the iodinated compound was ®rst examined with respect to structure and ef®cacy. Puri®cation of commercially prepared cold iodinated NDPMSH was performed to separate the mono-iodinated form from the di-iodinated and uniodinated NDPMSH. These forms were then examined for their ability to antagonize 125 I-NDPMSH binding to B 16 F 10 cells. These cells predominantly express the MC1R receptor. 19, 20 All forms of NDPMSH were equipotent in their ability to antagonize 125 I-NDPMSH binding to the cells (not shown). We then examined whether iodination affected the agonist effect on MC1R with respect to cAMP accumulation. All forms of the ligand were equipotent in their ability to stimulate cAMP production in B 16 F 10 cells (EC 50 0.6 nM). Finally, we examined the ability of agouti to antagonize these ligands ( Table 1) . As shown, agouti was equally effective in antagonizing all forms of the NDPMSH ligands' ability to increase intracellular cAMP levels.
Pharmacokinetics
Following the intravenous administration of Importantly, the maximal concentration in the serum observed with this compound, was as high as 100 nM. This indicated that adequate circulating NDPMSH was available to overcome the competitive inhibition seen by agouti on the MCRs.
Yellow mouse studies
Given the parameters for half-life in mice determined, we initiated a dose-response study in the C57Bla6J-A y (yellow obese) or C57Bla6J (control) mice. NDPMSH was administered subcutaneously twice daily in 15-week-old animals for 3 weeks. Interestingly, the animals' fur turned black in various areas (not just the dorsal injection site, Figure 2 ). There was no apparent effect of NDPMSH on body weight, blood glucose or blood insulin (not shown) at either the 1 mgakg or 5 mgakg dose. These doses are predicted to have serum concentrations no lower than 8 nM and 40 nM, respectively. Follow-up studies were then performed, to determine if this is speci®c for the animal strain background. A b-actin agouti transgenic line (BAP20) was 6 cells) in the absence of agouti and determined as described. 5 Agouti alone had no effect (not shown). Values are percent inhibition of cAMP level increase. -NDPMSH Pharmacokinetics. NDPMSH was radiolabeled and puri®ed as described in the`Material and Methods' section. The radiolabeled material was administered intravenously (i.v.) or subcutaneously (s.c.) in a saline solution. Blood was drawn at the indicated time points and parent compound (I 125 -NDPMSH) concentrations were determined using the HPLC method described.
Lack of NDPMSH effect on obesity MB Zemel et al used for the same study. Clear differences between transgenic and control mice were observed with respect to body weight increases, hyperinsulinaemia and hyperglycaemia (Table 2 and Table 3 ) at 12 weeks of age. In addition, leptin levels were highly elevated (5±10-fold) in the trangenics. Fat pad weights in all depots of the transgenics was greater than the controls, along with a 3-fold increase in adipocyte fatty acid synthase activity. However, none of these changes appeared to be signi®cantly in¯uenced by NDPMSH (10 mgakg) administration in either control or transgenics after 14 d. Although a number of criteria were examined, only core temperature was signi®cantly effected by injection of NDPMSH and this effect was observed in both control and agouti expressing lines. Basal core temperature for the agouti expressing line was signi®-cantly lower than that of the background control strain (Figure 3) . NDPMSH administration caused a marked increase in core temperature. However, this effect was of a similar magnitude in both strains of mice.
Discussion
We have shown that introduction of NDPMSH to mice overexpressing the agouti protein, can cause reversal of hair pigmentation from yellow to black, suggesting systemic availability of this compound. However, only one physiological parameter examined, core temperature, was affected by the concentration of NDPMSH used in this study. This effect was not in¯uenced by the presence of agouti. 3 AE 31.6*** 95.0 AE 25.2*** a n 5agroup. b 10 mgakg NDPMSH. * Signi®cant strain effect P`0.0001; ** Signi®cant strain effect P`0.001; *** Signi®cant strain effect P`0.05. Figure 2 Systemic availability of NDPMSH as evidenced by coat coloration. Agouti transgenic mice 4 were subcutaneously injected twice a day with either 10 mg NDPMSHakg body weight or saline (control) for 14 d prior to being photographed. After two weeks, the mice exhibit black fur in areas not localized to the dorsal injection site. .36*** a n 10agroup. b 10 mgakg NDPMSH. * Signi®cant strain effect P`0.05; ** Signi®cant strain effect P`0.01; *** Signi®cant strain effect P`0.0005.
Lack of NDPMSH effect on obesity MB Zemel et al
The concept that agouti overexpression induces diabetesaobesity via antagonism of melanocortin receptors is testable. We tried to ensure that the ligand, NDPMSH, was the best choice. NDPMSH is relatively stable in mice, with a half-life of about an hour. The molecule is a potent agonist of all members of the MCR family, so selective competition of the agouti from one MCR over another should not be a major issue. 11 Agouti and NDPMSH are competitive with respect to their ability to bind the MC1R receptor, so increasing concentrations of either should be suf®cient to counteract the opposing member. We examined the pharmacokinetic parameters of subcutaneously injected 125 I-NDPMSH (which behaves similarly to NDPMSH with respect to MC1R kinetic parameters). Our data indicates that the concentrations and methods used to introduce NDPMSH allowed NDPMSH concentrations in the blood suf®cient to activate MCRs.
A positive control included in the study is the production of black hair on the animal. Originally, we had plucked hair from the ventral side of the animal, while using dorsal injections of NDPMSH to determine whether the compound was systematically available. We found that black hair would appear in multiple locations outside the injection site, regardless of plucking. Thus, we can conclude that the compound was at least available to all portions of the skin. Additionally, we saw an NDPMSH-, but not agouti-, dependent effect on elevation of basal core temperature ( Figure 3 ). This effect has been observed by others 21 and indicates that the NDPMSH is available at high enough levels to effect this physiological parameter.
Therefore, the lack of effect of NDPMSH on reversingaaffecting insulin resistance and weight, may be explained by at least three possibilities: 1) Agouti mediates insulin sensitivity and weight gain through a receptor other than one from the MCR family; 2) Agouti mediates these effects through the MCRs, but not by antagonism of melanocortin ligands; or 3) NDPMSH may not be an appropriate ligand for these studies.
With respect to the ®rst issue, it is unlikely that agouti modulates energy homeostatis through receptors other than MCRs. Recently, it was shown that homologous recombinant knockout mice of the MC4R gene became obese and insulin resistant in a time course similar to that seen for yellow mice. 22 In addition, analogues of NDPMSH relatively selective for MC4R have been shown to reverse feeding behavior in mice upon intracerebroventricular introduction. 23 Both reports support the hypothesis that agouti-induced hyperphagia are mediated via MCRs, particularly MC4R.
It is also possible that agouti mediates its effects via MCRs, but not as a receptor antagonist. In fact, agouti can mobilize intracellular calcium in the absence of melanocortin ligands. 24 This calcium mobilization is dependent upon melanocortin receptors in HEK293 cells 25 and leads to the accumulation of triglycerides and elevation of fatty acid synthase activity in isolated adipocytes. 26 Finally, NDPMSH may not be the most appropriate ligand for these studies. The compound appears to display acceptable pharmacokinetics and access to the central nervous system, 27 albeit limited. However, the compound may not couple MCRs ef®ciently to the protein kinase A pathway. 28 It is interesting to note that NDPMSH administered intraperitoneally was somewhat effective in decreasing serum insulin and glucose. 23 However, these were relatively short term studies and the mode of administration was different to the current study. We believe there may be a short term effect of this peptide on glucoseainsulin, but longer term, this peptide does not show ef®cacy.
Conclusion
It is important to note that agouti induction of the obese phenotype is likely to be mediated by both central and peripheral mechanisms, which any be differently affected by melanocortin receptor antagonism. The observation that homologous recombinant knockout mice of the MC4R gene recapitulate several characteristics of the agouti obesity syndrome, 22 clearly implicates hypothalmic MC4R in the hyperphagia characteristic of agouti-induced obesity. The ®nding that intracerebroventricular administration of a potent cyclic melanocortin agonist (MTII) inhibits hyperphagia, while co-adminstration of a speci®c MC4R antagonist (SHU9119) reverses this administration, 23 reinforces this concept. On the other hand, direct effects of agouti on adipocyte Ca 2 signalling Figure 3 NDPMSH administration causes an elevation of core temperature. Mice, transgenic (n 10) and non-transgenic littermates (n 10), were administered NDPMSH subcutaneously and core temperature was measured as described (see`Methods and Materials' section). There was a clear effect of compound on elevation of core temperature.
Lack of NDPMSH effect on obesity MB Zemel et al and lipogenesis 24 ± 26 that are not inhibited by NDPMSH, argue for a peripheral effect of agouti which is not dependent on melanocortin receptor antagonism. In support of this concept, we have recently reported that transgenic mice expression agouti in adipose tissue under the control of the ap2 promoter, become obese in the presence of supplemental insulin, while insulin treated non-transgenic littermates do not. 29 This is consistent with our recent observation of an agouti-insulin synergism in stimulating lipogenesis in isolated adipocytes. 30 Thus, peripheral effects of agouti that are not predicated upon melanocortin receptor antagonism, appear to contribute to the agouti-induced obesity syndrome.
